NCT07087873 Assessment of Transcranial Alternating Current Stimulation's Clinical Efficacy in Treating Cognitive Impairment of Idiopathic Inflammatory Demyelinating Diseases
| NCT ID | NCT07087873 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Xuanwu Hospital, Beijing |
| Condition | Idiopathic Inflammatory Demyelinating Disorders of the Central Nervous System |
| Study Type | INTERVENTIONAL |
| Enrollment | 128 participants |
| Start Date | 2025-05-30 |
| Primary Completion | 2027-10-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 128 participants in total. It began in 2025-05-30 with a primary completion date of 2027-10-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to explore the imaging and electrophysiological characteristics of idiopathic inflammatory demyelinating diseases (IIDDs), and their correlation with clinical manifestations. It also evaluates the effectiveness of transcranial electrical stimulation in alleviating clinical symptoms of IIDDs patients, and analyzes the key factors affecting the treatment efficacy. By uncovering the overall and individual characteristics of IIDDs, this study seeks to enhance therapeutic outcomes through personalized neuromodulation programs. The findings will provide a basis for applying non-invasive brain stimulation (NIBS) in IIDDs treatment and offer new ideas for future personalized medicine approaches.
Eligibility Criteria
Inclusion Criteria: * Age: 18-60 years old. * Diagnosis: Patients with neuromyelitis optica spectrum disease, multiple sclerosis and other inflammatory demyelinating diseases of the central nervous system that meet the diagnostic criteria. * Medications have been stable for at least three months. Exclusion Criteria: * Recurrence has been recorded in the past 3 months. * Have a pacemaker or other metal implant in the body. * Impaired skin integrity at the site of electrode placement. * Previous organic brain disease such as epilepsy, hydrocephalus, central nervous system tumors, brain injury, or intracranial infection. * Combined with severe or unstable organic diseases, such as heart, liver and kidney and other organ dysfunction. * Pregnant or lactating women, those who are planning to become pregnant in the near future. * Patient compliance is poor. * In the opinion of the investigator, there is a situation that is not suitable to participate in this study.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07087873 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 60 Years, studying Idiopathic Inflammatory Demyelinating Disorders of the Central Nervous System. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07087873 currently recruiting?
Yes, NCT07087873 is actively recruiting participants. Contact the research team at huanghuijinmail@sina.com for enrollment information.
Where is the NCT07087873 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT07087873 clinical trial?
NCT07087873 is sponsored by Xuanwu Hospital, Beijing. The trial plans to enroll 128 participants.